New combo for tough leukemia shows promise, but trial cut short

NCT ID NCT05268003

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of three drugs—ponatinib, venetoclax, and mini-hyper CVD chemotherapy—in people with relapsed or refractory T-cell acute lymphoblastic leukemia. The goal was to see if the combo could improve remission rates. However, the study was terminated early after enrolling only 4 participants, so we have very little data on how well it works or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ponatinib, venetoclax, and mini-hyper CVD chemotherapy
What this could lead to: If it works, this could offer a new treatment option for patients with hard-to-treat T-cell acute lymphoblastic leukemia.
What could go wrong: The trial was terminated early with only 4 participants, so results are very limited. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA LEUKEMIA

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.